Early Detection Saves Lives: A Real World Breast Cancer Story
When it comes to cancer, there are a lot of myths and misconceptions out there. But the one thing is for certain: cancer can affect anyone, at any time, and from any background. Hear from one of our own about their battle with breast cancer and how early detection helped them defeat cancer.
It’s Not All about the Benjamins – Other Hurdles Presented by Research Participation, and why Payment won’t Resolve Them
C.K. Wang discusses payment for research participation in this exploratory workshop hosted by the Office for Human Research Protections in the U.S. Department of Health & Human Services.
Reflecting on Innovation and Hope during Blood Cancer Awareness Month
Every September, the healthcare, life sciences, and patient advocacy communities mark Blood Cancer Awareness Month, a time to focus on raising awareness about leukemia, lymphoma, myeloma, and other cancers that affect the blood or bone marrow.
RCTs and RWD: What are They and How do They Complement Each Other in Cancer Research?
In this new blog series from COTA and Deloitte, we will explore the expanding role of real-world data in oncology.
The COTA Team Expands as Demand for RWD Surges
2022 has been a time of extraordinary growth at COTA including many new faces that we are proud to welcome to our team.
COTA Descends on NYC for CAMP COTA
After two years, COTA was back together in NYC for an in-person all-hands meeting. As much as we have learned to adapt to the world of remote work, there is no substitute for the connection, collaboration, and energy that comes from physically being in the same space.
From Regulatory to RWD: A Journey to Improve Cancer Care with COTA
Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.
COTA Promotes Paige Whitney to Senior Vice President to Expand the Use of Real-World Data in Life Sciences
Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
The Roadmap for Making Clinical Trials More Diverse and Representative
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
COTA Collaborates with University of Chicago Medicine and UT Southwestern on Research To Be Presented at the American Society for Hematology’s Annual Meeting & Exposition
Four abstracts will be showcased at the American Society for Hematology’s (ASH) Annual Meeting & Exposition from December 11–14, 2021, in Atlanta, Georgia. COTA has the most comprehensive hematology oncology real-world data that is curated under the close guidance of leading oncologists and hematology specialists.
